anti–qki-5 Search Results


92
Antibodies Inc anti-qki-5 antibody
Anti Qki 5 Antibody, supplied by Antibodies Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti%E2%80%93qki-5/Anti-QKI-5+Antibody/custom%4075-232%4010%2E1101%2F2020%2E12%2E22%2E423880
Average 92 stars, based on 1 article reviews
anti-qki-5 antibody - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

90
NeuroMab mouse anti human qki 5
Mouse Anti Human Qki 5, supplied by NeuroMab, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti%E2%80%93qki-5/Anti-QKI-5+Antibody/pmc04821877-176-48-59
Average 90 stars, based on 1 article reviews
mouse anti human qki 5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
GenScript corporation anti–qki-5
Anti–Qki 5, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti%E2%80%93qki-5/anti+qki+5/pmc08139834-380-42-51
Average 90 stars, based on 1 article reviews
anti–qki-5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck & Co qki-5
Downregulation of <t>QKI-5</t> mRNA expression in ccRCC tissues and cell lines. (A) QKI-5 mRNA expression levels in 34 paired primary ccRCC tissues (T) and adjacent noncancerous tissues (N) were determined by qPCR assays. P < 0.001, paired t test. (B) qPCR analysis of QKI-5 expression in ccRCC cell lines and HK-2 immortalized renal proximal epithelial tubular cells. (C-E) Correlation of QKI-5 gene expression with tumor T stage, M status, and grade of differentiation. chi-square test, Primary data were taken from TCGA ccRCC data set (https://tcga-data.nci.nih.gov/tcga/). The boxes represent the 25th to 75thpercentiles, and horizontal lines within the box represent median values. The whiskers represent the lowest and highest value in the 25th percentile minus 1.5IQR and 75th percentile plus 1.5IQR regions, respectively. (C)The 25thpercentiles,75thpercentiles,median in T1-2: 9.751695, 10.82361, 10.24365;T3-4: 9.427069, 10.51334, 9.962113.(D) The 25thpercentiles,75thpercentiles,median in M0: 9.651339, 10.74372, 10.19386;M1: 9.514634, 10.50172, 9.968011.(E) the 25thpercentiles,75thpercentiles,median in G1-2: 9.701859, 10.8063, 10.24195;G3-4: 9.547901, 10.6237, 10.04023.(F) Kaplan-Meier survival curve of overall survival for QKI-5 expression in 513 mLRCC patients from TCGA ccRCC dataset (https://tcga-data.nci.nih.gov/tcga/).
Qki 5, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti%E2%80%93qki-5/qki5+anti/pmc05134695-348-8-9
Average 90 stars, based on 1 article reviews
qki-5 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
This is a recombinant monoclonal antibody.
  Buy from Supplier

N/A
Our Anti-QKI-5 mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N195A/16. It detects human, mouse, and rat QKI-5, and is purified by Protein A chromatography. It is great for use in
  Buy from Supplier

Image Search Results


Downregulation of QKI-5 mRNA expression in ccRCC tissues and cell lines. (A) QKI-5 mRNA expression levels in 34 paired primary ccRCC tissues (T) and adjacent noncancerous tissues (N) were determined by qPCR assays. P < 0.001, paired t test. (B) qPCR analysis of QKI-5 expression in ccRCC cell lines and HK-2 immortalized renal proximal epithelial tubular cells. (C-E) Correlation of QKI-5 gene expression with tumor T stage, M status, and grade of differentiation. chi-square test, Primary data were taken from TCGA ccRCC data set (https://tcga-data.nci.nih.gov/tcga/). The boxes represent the 25th to 75thpercentiles, and horizontal lines within the box represent median values. The whiskers represent the lowest and highest value in the 25th percentile minus 1.5IQR and 75th percentile plus 1.5IQR regions, respectively. (C)The 25thpercentiles,75thpercentiles,median in T1-2: 9.751695, 10.82361, 10.24365;T3-4: 9.427069, 10.51334, 9.962113.(D) The 25thpercentiles,75thpercentiles,median in M0: 9.651339, 10.74372, 10.19386;M1: 9.514634, 10.50172, 9.968011.(E) the 25thpercentiles,75thpercentiles,median in G1-2: 9.701859, 10.8063, 10.24195;G3-4: 9.547901, 10.6237, 10.04023.(F) Kaplan-Meier survival curve of overall survival for QKI-5 expression in 513 mLRCC patients from TCGA ccRCC dataset (https://tcga-data.nci.nih.gov/tcga/).

Journal: Cell Cycle

Article Title: RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA

doi: 10.1080/15384101.2016.1235103

Figure Lengend Snippet: Downregulation of QKI-5 mRNA expression in ccRCC tissues and cell lines. (A) QKI-5 mRNA expression levels in 34 paired primary ccRCC tissues (T) and adjacent noncancerous tissues (N) were determined by qPCR assays. P < 0.001, paired t test. (B) qPCR analysis of QKI-5 expression in ccRCC cell lines and HK-2 immortalized renal proximal epithelial tubular cells. (C-E) Correlation of QKI-5 gene expression with tumor T stage, M status, and grade of differentiation. chi-square test, Primary data were taken from TCGA ccRCC data set (https://tcga-data.nci.nih.gov/tcga/). The boxes represent the 25th to 75thpercentiles, and horizontal lines within the box represent median values. The whiskers represent the lowest and highest value in the 25th percentile minus 1.5IQR and 75th percentile plus 1.5IQR regions, respectively. (C)The 25thpercentiles,75thpercentiles,median in T1-2: 9.751695, 10.82361, 10.24365;T3-4: 9.427069, 10.51334, 9.962113.(D) The 25thpercentiles,75thpercentiles,median in M0: 9.651339, 10.74372, 10.19386;M1: 9.514634, 10.50172, 9.968011.(E) the 25thpercentiles,75thpercentiles,median in G1-2: 9.701859, 10.8063, 10.24195;G3-4: 9.547901, 10.6237, 10.04023.(F) Kaplan-Meier survival curve of overall survival for QKI-5 expression in 513 mLRCC patients from TCGA ccRCC dataset (https://tcga-data.nci.nih.gov/tcga/).

Article Snippet: 44,45 The primary antibodies used included those for QKI-5 (Merck, 03–112); RASA1 (Santa Cruz, SC-63); cyclin A, D1, and E; p21; p27 (all from Santa Cruz Biotechnology); and α-tubulin (Sigma, T6199), as well as a number of antibodies from Cell Signaling Technology, including those for ERK (4780), phospho-ERK1/2 (5726), p38(8690), phospho-p38 (Thr180/Tyr182, 4511), and Raf-1 (9422).

Techniques: Expressing

Overexpression of QKI-5 inhibits the proliferation of ccRCC cells in vitro and in vivo. (A–E) 786-O and A-498 cells with stably overexpressing QKI-5 or transfected with empty vector (Vec) were analyzed as follows. (A) QKI-5 mRNA expression levels were determined by qPCR assays. (B) QKI-5 protein expression levels were determined by immunoblotting; α-tubulin was used as a loading control. (C) Cell proliferation was determined by the MTS assay; (D) Colony formation ability; representative micrographs (left) and quantification (right) of crystal violet-stained cells from 3 independent experiments; (E) Control or QKI-5-overexpressing 786-O cells were inoculated subcutaneously into nude mice (n = 5/group). Tumor volumes were measured (left) and weighed (right) on the last days of the experiment. Representative images of isolated tumors (middle) are presented; *P < 0.05, **P < 0.01, student's t-test.

Journal: Cell Cycle

Article Title: RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA

doi: 10.1080/15384101.2016.1235103

Figure Lengend Snippet: Overexpression of QKI-5 inhibits the proliferation of ccRCC cells in vitro and in vivo. (A–E) 786-O and A-498 cells with stably overexpressing QKI-5 or transfected with empty vector (Vec) were analyzed as follows. (A) QKI-5 mRNA expression levels were determined by qPCR assays. (B) QKI-5 protein expression levels were determined by immunoblotting; α-tubulin was used as a loading control. (C) Cell proliferation was determined by the MTS assay; (D) Colony formation ability; representative micrographs (left) and quantification (right) of crystal violet-stained cells from 3 independent experiments; (E) Control or QKI-5-overexpressing 786-O cells were inoculated subcutaneously into nude mice (n = 5/group). Tumor volumes were measured (left) and weighed (right) on the last days of the experiment. Representative images of isolated tumors (middle) are presented; *P < 0.05, **P < 0.01, student's t-test.

Article Snippet: 44,45 The primary antibodies used included those for QKI-5 (Merck, 03–112); RASA1 (Santa Cruz, SC-63); cyclin A, D1, and E; p21; p27 (all from Santa Cruz Biotechnology); and α-tubulin (Sigma, T6199), as well as a number of antibodies from Cell Signaling Technology, including those for ERK (4780), phospho-ERK1/2 (5726), p38(8690), phospho-p38 (Thr180/Tyr182, 4511), and Raf-1 (9422).

Techniques: Over Expression, In Vitro, In Vivo, Stable Transfection, Transfection, Plasmid Preparation, Expressing, Western Blot, MTS Assay, Staining, Isolation

QKI-5 directly upregulated RASA1 expression via regulating its mRNA stability. (A and B) mRNA expression levels were determined by real-time qPCR assays. The expression levels of RASA1 were significantly upregulated in 786-O and A-498 cells stably overexpressing QKI-5, whereas that of Axl, Frk, Igfbp7 and Ahr were not. *P< 0.05, Student t test. (C and D) QKI-5 and RASA1 mRNA expression was significantly downregulated in the matched primary ccRCC tissues (T) in contrast to the adjacent noncancerous tissues (N). (E) RASA1 mRNA levels were positively correlated with QKI-5 expression in 34 pairs of ccRCC tissues as determined by real-time qPCR (GAPDH was used as reference genes. Linear regression was indicated, r2 = 0.5293; P < 0.0001).(F) Immunoblotting analysis of RASA1 in control or QKI-5-overexpressing 786-O and A-498 cells, α-tubulin was used as a loading control. Data presented here are a representative of 3 different experiments. Densitometry of Western blot to analyze the relative protein expression by using Image J software (G) Direct interaction between RASA1 and QKI-5. QKI-5 overexpressing 786-O cells were immunoprecipitated with anti- QKI-5 antibody or the negative control IgG. The presence of RASA1 mRNA in the immunoprecipitation was detected by RT-PCR and visualized by ethidium bromide staining.

Journal: Cell Cycle

Article Title: RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA

doi: 10.1080/15384101.2016.1235103

Figure Lengend Snippet: QKI-5 directly upregulated RASA1 expression via regulating its mRNA stability. (A and B) mRNA expression levels were determined by real-time qPCR assays. The expression levels of RASA1 were significantly upregulated in 786-O and A-498 cells stably overexpressing QKI-5, whereas that of Axl, Frk, Igfbp7 and Ahr were not. *P< 0.05, Student t test. (C and D) QKI-5 and RASA1 mRNA expression was significantly downregulated in the matched primary ccRCC tissues (T) in contrast to the adjacent noncancerous tissues (N). (E) RASA1 mRNA levels were positively correlated with QKI-5 expression in 34 pairs of ccRCC tissues as determined by real-time qPCR (GAPDH was used as reference genes. Linear regression was indicated, r2 = 0.5293; P < 0.0001).(F) Immunoblotting analysis of RASA1 in control or QKI-5-overexpressing 786-O and A-498 cells, α-tubulin was used as a loading control. Data presented here are a representative of 3 different experiments. Densitometry of Western blot to analyze the relative protein expression by using Image J software (G) Direct interaction between RASA1 and QKI-5. QKI-5 overexpressing 786-O cells were immunoprecipitated with anti- QKI-5 antibody or the negative control IgG. The presence of RASA1 mRNA in the immunoprecipitation was detected by RT-PCR and visualized by ethidium bromide staining.

Article Snippet: 44,45 The primary antibodies used included those for QKI-5 (Merck, 03–112); RASA1 (Santa Cruz, SC-63); cyclin A, D1, and E; p21; p27 (all from Santa Cruz Biotechnology); and α-tubulin (Sigma, T6199), as well as a number of antibodies from Cell Signaling Technology, including those for ERK (4780), phospho-ERK1/2 (5726), p38(8690), phospho-p38 (Thr180/Tyr182, 4511), and Raf-1 (9422).

Techniques: Expressing, Stable Transfection, Western Blot, Software, Immunoprecipitation, Negative Control, Reverse Transcription Polymerase Chain Reaction, Staining

QKI-5 inhibits the proliferation of ccRCC cells via regulating RASA1 and the RAS-MAPK signaling pathway. (A and B) QKI-5-expressing and control A-498 cells were transiently transfected with RASA1siRNA (si-rasa1-1,si-rasa1-3) or scrambled control siRNA (si-ctrl). RASA1 expression levels were evaluated by real-time qPCR assays (A) and immunoblotting analysis(B). (C) MTS analysis of cell proliferation in A-498 cells described in A. (** p,0.01, Student's t-test). (D) Immunoblotting was used to assess the regulatory effect of QKI-5 and RASA1 in the regulation of RAS signaling pathway.

Journal: Cell Cycle

Article Title: RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA

doi: 10.1080/15384101.2016.1235103

Figure Lengend Snippet: QKI-5 inhibits the proliferation of ccRCC cells via regulating RASA1 and the RAS-MAPK signaling pathway. (A and B) QKI-5-expressing and control A-498 cells were transiently transfected with RASA1siRNA (si-rasa1-1,si-rasa1-3) or scrambled control siRNA (si-ctrl). RASA1 expression levels were evaluated by real-time qPCR assays (A) and immunoblotting analysis(B). (C) MTS analysis of cell proliferation in A-498 cells described in A. (** p,0.01, Student's t-test). (D) Immunoblotting was used to assess the regulatory effect of QKI-5 and RASA1 in the regulation of RAS signaling pathway.

Article Snippet: 44,45 The primary antibodies used included those for QKI-5 (Merck, 03–112); RASA1 (Santa Cruz, SC-63); cyclin A, D1, and E; p21; p27 (all from Santa Cruz Biotechnology); and α-tubulin (Sigma, T6199), as well as a number of antibodies from Cell Signaling Technology, including those for ERK (4780), phospho-ERK1/2 (5726), p38(8690), phospho-p38 (Thr180/Tyr182, 4511), and Raf-1 (9422).

Techniques: Expressing, Transfection, Western Blot

QKI-5 promotes cell cycle arrest at the G1/S-phase transition through P27 and Cyclin D1, involving MAPK signaling pathway. (A and B) 786-O or A-498 cells stably overexpressing QKI-5 or transfected with empty vector (Vec) were subjected to cell cycle analysis by flow cytometry. Images and qualification of the cell cycle distribution in 3 experiments are shown; *P < 0.05, **P < 0.01, Student t test. (C) Immunoblotting analysis of cyclin A, cyclin D1, cyclin E, and their inhibitors p21 and p27 in the indicated cell lines. α-tubulin was used as a loading control. (D) Immunoblotting analysis of phosphorylated ERK, total ERK, phosphorylated p38, and total p38 in the indicated cell lines. α-tubulin was used as the loading control.

Journal: Cell Cycle

Article Title: RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA

doi: 10.1080/15384101.2016.1235103

Figure Lengend Snippet: QKI-5 promotes cell cycle arrest at the G1/S-phase transition through P27 and Cyclin D1, involving MAPK signaling pathway. (A and B) 786-O or A-498 cells stably overexpressing QKI-5 or transfected with empty vector (Vec) were subjected to cell cycle analysis by flow cytometry. Images and qualification of the cell cycle distribution in 3 experiments are shown; *P < 0.05, **P < 0.01, Student t test. (C) Immunoblotting analysis of cyclin A, cyclin D1, cyclin E, and their inhibitors p21 and p27 in the indicated cell lines. α-tubulin was used as a loading control. (D) Immunoblotting analysis of phosphorylated ERK, total ERK, phosphorylated p38, and total p38 in the indicated cell lines. α-tubulin was used as the loading control.

Article Snippet: 44,45 The primary antibodies used included those for QKI-5 (Merck, 03–112); RASA1 (Santa Cruz, SC-63); cyclin A, D1, and E; p21; p27 (all from Santa Cruz Biotechnology); and α-tubulin (Sigma, T6199), as well as a number of antibodies from Cell Signaling Technology, including those for ERK (4780), phospho-ERK1/2 (5726), p38(8690), phospho-p38 (Thr180/Tyr182, 4511), and Raf-1 (9422).

Techniques: Sublimation, Stable Transfection, Transfection, Plasmid Preparation, Cell Cycle Assay, Flow Cytometry, Western Blot